Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
-

Ratings ESG MSCI

Ratings PHARMING GROUP: Strengths and Weaknesses

Rating Financials

PHARMING GROUP SectorNetherlands

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

-

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

PHARMING GROUP SectorNetherlands

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

-

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

PHARMING GROUP SectorNetherlands

Consensus

Analysts' buy/sell recommendations

-

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

PHARMING GROUP SectorNetherlands

Visibility

-

Analysts' coverage

Financial estimates divergence

-

Analysts' recommendations divergence

-

Analysts' Target price divergence

Surprise rates

Rating Revisions

PHARMING GROUP SectorNetherlands

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
816M - -
1,047B
A
646B -
BBB
- -
451B
AA
-
355B
AA
291B
AAA
252B
A
234B
A
203B
A
181B
AA
Average 366.01B
AA
Weighted average by Cap.
AA